LRP5: the protein that stops clots without triggering bleeding

Researchers have identified the LRP5 protein as a missing link in thrombosis prevention: its genetic deletion and pharmacological inhibition significantly reduce platelet aggregation and clot formation in preclinical models, yet without the bleeding complications that currently limit the use of classic antiplatelet drugs. Studies in human platelets and LRP5-deficient mice showed that elimination or pharmacological blockade of this WNT pathway protein substantially prolonged carotid occlusion time and reduced flow-mediated platelet deposition on collagen surfaces, while genetic deletion did not significantly affect normal coagulation or induce bleeding. This finding opens a critical window for the longevity-conscious reader: whereas conventional antithrombotic agents impose a tradeoff between preventing cardiovascular events and tolerating chronic hemorrhagic risk, LRP5 represents a more selective pathway that specifically modulates pathological platelet reactivity without undermining the physiologic hemostasis necessary for survival.